Abstract
BackgroundMelanoma mortality has steadily decreased since the introduction of immune checkpoint inhibitors (ICIs) to manage advanced-stage disease (stage III/IV).1 Although ICIs have prolonged survival, this therapeutic class is associated with...
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have